How Kite Pharma Evaluates Combinatorial Therapeutic Targets Using Spatial Proteomics | RareCyte Webinar

             

Article adapted from RareCyte.

Developing next-generation therapies that address multiple therapeutic targets requires a clear understanding of how those targets are expressed and combined within patient tissues.

On November 18, 2026 (US Eastern Time), William Mifsud, PhD, Head of Pathology Research at Kite Pharma, a Gilead Company, will join a RareCyte webinar to discuss this important challenge in precision therapeutics.

The webinar will explore how Kite Pharma uses the Orion™ multiplex immunofluorescence imaging platform to investigate therapeutic target expression and co-expression across large tissue cohorts. Attendees will gain insights into how a pharmaceutical pathology team applies these findings to inform clinical trial design.

On-demand viewing planned: A recording of the webinar is expected to be available after the live event. If you are unable to attend the live session, we encourage you to register in advance and watch the webinar on demand.

Why Does Co-Expression Matter in Precision Therapeutics?

Precision medicine seeks to develop therapeutic strategies based on the molecular characteristics of patients. For therapies directed against multiple biomarkers, measuring the expression of each target individually may not provide all the information needed.

Researchers may need to address questions such as:

  • Are multiple therapeutic targets expressed within the same cells?
  • How are target-expressing cells distributed throughout the tissue?
  • How frequently do specific combinations of targets occur across a patient population?
  • How can these findings inform patient population selection and clinical trial design?

Spatial proteomics offers an approach to investigating these questions by combining protein expression measurements with information about their location within the tissue.

How Is Kite Pharma Using Orion™?

The webinar will introduce how Kite Pharma’s pathology research team investigates the expression of multiple therapeutic targets across large tissue cohorts.

A key focus will be the integration of visual pathology assessment and quantitative image analysis.

By examining tissue morphology and biomarker expression patterns alongside quantitative measurements of target co-expression, researchers can investigate therapeutic target combinations from multiple perspectives.

The webinar will also feature a live demonstration using actual Orion™ imaging data and discuss the development of customized multiplex immunofluorescence panels tailored to specific research objectives.

Four Key Topics Covered in the Webinar

1. Evaluating Therapeutic Targets Across Large Tissue Cohorts

Explore research approaches for assessing multiple therapeutic targets and their expression combinations across tissue samples.

2. Integrating Pathology Assessment and Quantitative Analysis

Learn how visual pathology review and quantitative image analysis can be combined to characterize and measure biomarker co-expression.

3. Live Demonstration Using Actual Orion™ Data

See a practical approach to investigating therapeutic target expression patterns using imaging data acquired on Orion™.

4. Developing Custom Multiplex Immunofluorescence Panels

Discover how a small pathology research team develops customized panels to address complex biomarker research questions.

Meet the Speakers

William Mifsud, PhD, Head of Pathology Research at Kite Pharma
William Mifsud, PhD

William Mifsud, PhD

Kite Pharma, A Gilead Company
Senior Director, Non-Clinical Safety / Head of Pathology Research

Dr. Mifsud received his doctorate in developmental biology and embryology from the University of Cambridge. His background includes extensive work in pathology and translational research, with publications covering pediatric and cancer pathology, tumor biology, genomics, cellular therapies, and digital and computational pathology.

Tad George, PhD, Senior Vice President of Biology R&D at RareCyte
Tad George, PhD

Tad George, PhD

RareCyte, Inc.
Senior Vice President, Biology R&D

Dr. George has more than two decades of experience advancing innovative scientific instrumentation for fundamental research, drug discovery, and clinical applications. Before joining RareCyte, he held leadership roles at Biodesy and DVS Sciences and led the biology department at Amnis Corporation. He received his PhD in immunology from UT Southwestern Medical Center and completed postdoctoral research at Immunex Corporation.

Webinar Details and Registration

RareCyte WEBINAR

Evaluating Combinatorial Targets for Precision Therapeutics: A Pathologist’s View

  • Date and time (US Eastern Standard Time):Wednesday, November 18, 2026, 12:00–1:00 PM EST
  • Date and time (Japan Standard Time):Thursday, November 19, 2026, 2:00–3:00 AM JST
  • Format:Online webinar
  • Duration:60 minutes
  • On-demand viewing:Planned following the live event

On-Demand Viewing Planned

A recording of the webinar is expected to be available after the live event. For those unable to attend the live session due to time zone differences or scheduling conflicts, we encourage you to register in advance and watch the webinar on demand.

Learn More and Register for the Webinar

You will be redirected to the official Fierce Pharma registration page.

This webinar offers researchers working in oncology drug discovery, cell therapy, translational research, and biomarker development an opportunity to explore the application of spatial proteomics in therapeutic development.


Article source: RareCyte official webinar page
Speaker information and photographs: Fierce Pharma official webinar registration page
Information verified on November 16, 2026.